1IY0 Stock Chart & Stats
€93.20
-€4.40(-4.61%)
At close: 4:00 PM EDT
€93.20
-€4.40(-4.61%)
Day’s Range― - ―
52-Week Range€35.40 - €103.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€563.74M
Enterprise Value€656.75
Total Cash (Recent Filing)€134.30M
Total Debt (Recent Filing)€107.83K
Price to Earnings (P/E)―
Beta9.57
Next Earnings
Nov 06, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding6,712,172
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€107.30Price Target Upside15.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress Toward Potential U.S. Market EntryThe rolling NDA submission marks meaningful progress toward potential commercialization of ALXN1840 in Wilson disease. Advancing completed sections to the FDA can shorten regulatory sequencing and provides a clearer path from late-stage development to a possible product launch, although approval remains uncertain.
Late-stage Clinical Efficacy And TolerabilityPositive Phase 3 results provide substantive support for ALXN1840’s clinical differentiation, particularly its sustained neurologic improvement and copper mobilization. Favorable safety data across 645 patient-years may strengthen regulatory credibility and the product’s potential positioning in rare disease care.
Strong Low-leverage Balance SheetExtremely low leverage limits fixed financial obligations and reduces near-term solvency risk while Monopar funds clinical and regulatory work. Its sizable reported equity and asset base provides greater flexibility than a highly indebted development-stage biotech, despite continuing losses.
Bears Say
No Recurring Product RevenueZero reported revenue confirms that Monopar has not yet reached commercial scale and cannot currently fund operations through recurring product sales. Until a candidate is approved and launched, financial progress remains dependent on development outcomes and access to external capital.
Persistent And Widening Net LossesThe widening loss trajectory indicates that research and development spending continues without offsetting commercial revenue in the reported periods. Ongoing earnings deterioration can erode the capital base over time and increases the importance of successful clinical advancement and eventual commercialization.
Ongoing Cash Burn And Reliance On External FundingConsistently negative operating and free cash flow mean Monopar is not self-funding its development program. Even excluding the reported TTM anomaly, prior annual cash burn implies continued reliance on financing activities, which can constrain strategic flexibility and dilute existing holders.
Monopar Therapeutics Inc News
1IY0 FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was €35.40 and its highest was €103.40 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is €563.74M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Nov 06, 2026 which is in 46 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -€0.54 earnings per share for the quarter, beating the consensus estimate of -€0.56 by €0.02.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.7.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,712,172 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -€0.54 in its last earnings report, beating expectations of -€0.56. Following the earnings report the stock price went down -1.521%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:1IY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monopar Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€107.30 (15.13% Upside)
€107.30 (15.13% Upside)
Blogger Sentiment
Bullish
DE:1IY0 Sentiment 100%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
150.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
1IY0 Stock 12 Month Forecast
Average Price Target
€107.30
▲(15.13% Upside)
Technical Analysis
CytomX Therapeutics
―
Kura Oncology
―
Replimune Group
―
Oric Pharmaceuticals
―
Candel Therapeutics
―